Table 2.
Post-propensity matched characteristics of HCV uninfected recipients from HCV uninfected donors (HCV D Ab−, NAT−/R Ab−), vs. HCV seropositive, non-viremic donors (HCV D Ab+,NAT−/R Ab−) and HCV viremic (HCV Ab±, NAT+/R−) donors.*
| D Ab−, NAT− / R Ab− (n = 654) | D Ab+, NAT− / R Ab− (n = 349) | p value | D Ab−, NAT− / R Ab− (n = 340) | D Ab+−, NAT+/ R Ab− (n =191) | p value | |
|---|---|---|---|---|---|---|
| Age (SD) year | 57.5 (10.7) | 57.6 (11.6) | 0.83 | 57.6 (10.4) | 59.1 (10.5) | 0.12 |
| Gender male, n (%) | 430 (65.8) | 229 (65.6) | 0.97 | 259 (76.2) | 148 (77.5) | 0.73 |
| African American race, n (%) | 192 (29.4) | 104 (29.8) | 0.88 | 136 (40.0) | 77 (40.3) | 0.94 |
| Diabetes (any type), n (%) | 290 (44.3) | 157 (45.0) | 0.85 | 158 (46.7) | 93 (48.7) | 0.62 |
| Previous renal transplant, n (%) | 49 (7.5) | 25 (7.2) | 0.85 | 24 (7.1) | 12 (6.3) | 0.73 |
| Diagnosis, n (%) | 0.83 | 0.99 | ||||
| Glomerulonephritis | 108 (16.5) | 53 (15.2) | 47 (13.8) | 23 (12.0) | ||
| Hypertension | 131 (20.0) | 80 (22.9) | 77 (22.7) | 44 (23.0) | ||
| DM | 242 (37.0) | 120 (34.4) | 114 (33.5) | 66 (34.6) | ||
| PKD | 53 (8.1) | 39 (11.2) | 32 (9.4) | 18 (9.4) | ||
| Others | 120 (18.4) | 57 (16.3) | 70 (20.1) | 40 (20.9) | ||
| cPRA, n (%) | 0.66 | 0.57 | ||||
| 0–20 | 515 (78.8) | 277 (79.4) | 297 (87.4) | 169 (88.5) | ||
| 21–80 | 90 (13.8) | 51 (14.6) | 22 (6.5) | 14 (7.3) | ||
| 81–100 | 49 (7.5) | 21 (6.0) | 21 (6.2) | 8 (4.2) | ||
| mean (SD) | 14.8 (29.3) | 13.3 (26.9) | 0.42 | 10.1 (26.7) | 7.8 (22.1) | 0.29 |
| Days on waitlist, mean (SD) | 823 (847) | 816 (794) | 0.91 | 558 (711) | 429 (541) | 0.03 |
| Dialysis duration prior to listing (years), n (%) | 0.88 | 0.02 | ||||
| Preemptive | 98 (15.0) | 55 (15.8) | 70 (20.6) | 38 (19.9) | ||
| ≤1 | 185 (28.3) | 92 (26.3) | 99 (29.2) | 55 (29.0) | ||
| 1–3 | 207 (31.7) | 117 (33.5) | 103 (30.3) | 74 (38.7) | ||
| >3 | 163 (25.0) | 85 (24.4) | 60 (17.6) | 16 (8.4) | ||
| Mean† (SD) | 2.3 (3.2) | 2.1 (2.7) | 0.18 | 2.4 (2.9) | 1.5 (1.6) | <0.001 |
| Allocation type, n (%) | 0.07 | 0.08 | ||||
| Local | 229 (35.0) | 98 (28.1) | 100 (29.4) | 39 (20.4) | ||
| Regional | 186 (28.4) | 105 (30.1) | 92 (27.1) | 60 (31.4) | ||
| National | 239 (36.5) | 146 (41.8) | 148 (43.5) | 92 (48.2) | ||
| DCD, n (%) | 108 (16.5) | 59 (16.9) | 0.87 | 33 (9.7) | 17 (8.9) | 0.76 |
| KDPI %, n (%) | 0.62 | 0.01 | ||||
| 0–20 | 16 (2.5) | 1 (0.3) | 15 (0.9) | 1 (0.5) | ||
| 21–50 | 201 (30.7 | 113 (32.3) | 165 (48.5) | 106 (55.5) | ||
| 51–80 | 300 (45.8) | 163 (46.7) | 141 (41.5) | 81 (42.1) | ||
| 81–100 | 137 (21) | 72 (20.6) | 19 (5.6) | 3 (1.6) | ||
| CIT mean (SD), hours | 19.1 (7.4) | 18.7 (7.1) | 0.41 | 19.1 (7.4) | 18.8 (7.4) | 0.61 |
| Induction Immunosuppression | 0.89 | 0.78 | ||||
| No-induction | 29 (4.4) | 17 (4.9) | 15 (4.3) | 7 (3.7) | ||
| IL2-RA | 96 (14.7) | 55 (15.8) | 54 (15.4) | 31 (16.2) | ||
| r-ATG | 417 (63.8) | 204 (58.5) | 265 (75.7) | 145 (75.9) | ||
| Alemtuzumab | 112 (17.1) | 73 (20.9) | 16 (4.6) | 8 (4.2) |
Ab, Antibody; CIT, Cold Ischemia time; cPRA, Calculated panel reactive antibodies; DCD, Donation after cardiac death; D, Donor; HCV, Hepatitis C Virus; IL-2RA, Interleukin 2 receptor antagonist, KDPI %, Kidney Donor Profile Index; PKD, Polycystic Kidney Disease; r-ATG, Rabbit Antithymocyte globulin; R, Recipient; SD, Standard deviation.
The propensity matching was performed based on variables including recipient age (year), gender, race (AA, non-AA), cause of ESRD (DM, HTN, GN, PKD, others), diabetes status, re-transplant status, share type (local, regional, national), donor DCD status, induction type (no-induction, IL2-RA, r-ATG, alemtuzumab), cold ischemia time (hour), donor KDPI score category (0–20, 21–50, 51–80, 81–100%), cPRA (0–20%, 21–80%, 81–100%), wait-list time (0–1, 1–3, >3 years), and dialysis vintage (preemptive, 0–1, 1–3, >3 years).
If not pre-emptive.